Sales of pulmonary fibrosis biomarkers are expected to accelerate at a CAGR of 4.4% from 2024 to 2034. The pulmonary fibrosis biomarker market is projected to increase from US$ 4,353.0 million in 2024 to US$ 6,538.4 million by 2034. The market was valued at US$ 4,149.0 million in 2023.
Increased developments in pulmonary fibrosis biomarkers, making it easier to find and validate new biomarkers and integrate them into clinical practice, contribute to the market expansion of pulmonary fibrosis biomarkers. The market is witnessing growth due to the application of bioinformatics tools and the development of high-throughput screening techniques.
| Attributes | Details |
|---|---|
| Pulmonary Fibrosis Biomarker Market Size (2024) | US$ 4,353.0 million |
| Expected Market Size (2034) | US$ 6,538.4 million |
| CAGR (2024 to 2034) | 4.4% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Attributes | Details |
|---|---|
| Pulmonary Fibrosis Biomarker Market Value (2018) | US$ 3,330.6 million |
| Estimated Market Value for 2023 | US$ 4,149.0 million |
| CAGR from 2019 to 2023 | 4.5% |
Principal Consultant
| Top Type | Segment Share (2024) |
|---|---|
| Imaging Tests | 50.8% |
| Top Indication | Segment Share (2024) |
|---|---|
| Idiopathic pulmonary fibrosis (IPF) | 42.6% |
| Top End User | Segment Share (2024) |
|---|---|
| Hospitals | 33.4% |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
This section examines the pulmonary fibrosis biomarker markets in several significant economies, such as the United States, Spain, the United Kingdom, India, and China. It also explores different factors that influence pulmonary fibrosis biomarker demand, adoption, and sales across these countries.
| Country | CAGR (2024 to 2034) |
|---|---|
| China | 11.4% |
| India | 6.9% |
| Spain | 8.2% |
| United States | 3.5% |
| Germany | 5.5% |
Key pulmonary fibrosis biomarker manufacturers significantly shape the sector's competitive landscape. Known for its dedication to innovation, Biogen welcomes Veracyte, which is one of the significant pulmonary fibrosis biomarker providers, emphasizing cutting-edge diagnostic solutions.
Galapagos NV offers its advantages to the market, while Genentech, a Roche company, adds its pharmaceutical knowledge. Biocartis and Myriad Genetics are essential in pulmonary fibrosis biomarkers since they offer specific solutions.
These key pulmonary fibrosis biomarker vendors work together to enhance research and development, which supports the market's general expansion and development for pulmonary fibrosis biomarkers. Their combined efforts highlight the pulmonary fibrosis biomarker industry's dynamic nature as it continues to tackle the difficulties related to pulmonary fibrosis.
Latest Advancements
The pulmonary fibrosis biomarker was valued at US$ 4,149.0 million in 2023.
The demand for pulmonary fibrosis biomarkers is set to reach a valuation of US$ 6,538.4 million by the end of 2034.
The market is anticipated to expand at a 4.4% CAGR through 2034.
The imaging tests segment is expected to acquire a market share of 44.9% in 2024.
Sales of pulmonary fibrosis biomarkers are estimated to be valued at US$ 4,353.0 million in 2024.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Area Development/Innovation Trends
4. Value Added Insights
4.1. Product Assessment
4.1.1. Product Adoption Analysis
4.1.2. Product USP's/Features Analysis
4.1.3. Recent Product Launches and Innovations
4.2. Regulatory Guidelines
4.2.1. Legal Requirements and Frameworks in the USA
4.2.2. Legal Requirements and Frameworks in Europe
4.2.3. Legal Requirements and Frameworks in Japan
4.2.4. Legal Requirements and Frameworks in China
4.2.5. Legal Requirements and Frameworks in India
4.2.6. Legal Requirements and Frameworks in Australia
4.3. Disease Epidemiology, By Key Countries
4.3.1. Prevalence of Population, By Country
4.3.2. Gender and Age-Specific Cases
4.3.3. Severity-Specific Cases
4.3.4. Diagnosed Prevalence Cases
4.4. Pipeline Assessment
4.4.1. Comprehensive Assessment by End Users
4.4.2. By Disease Indication
4.4.3. Emerging Novel trends
4.4.4. Late-stage Pipeline Assessment
4.5. Porter’s Analysis
4.6. Regional PESTEL Analysis
4.7. Value Chain Analysis
4.8. Unmet Needs Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure Outlook
5.1.2. Global Life Expectancy Outlook
5.1.3. R & D Funding By Region
5.1.4. R & D Funding By Country
5.1.5. R & D Spending, By Pharma Players
5.1.6. Top 25 Companies by R & D Spend in 2023
5.1.7. Parent Market Outlook
5.2. Forecast Factors - Relevance and Impact
5.2.1. Regulatory Initiatives and Incentives
5.2.2. Technological Advancements in Trial Design
5.2.3. Patient-Centric Approaches and Advocacy
5.2.4. Global Collaborations and Partnerships
5.2.5. Increased Focus on Rare Diseases
5.2.6. Inclusive Trial Designs for Diverse Populations
5.2.7. Ethical Considerations and Informed Consent
5.2.8. Advancements in Pediatric Precision Medicine
5.2.9. Integration of Real-World Evidence (RWE)
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand (in Value or Size in US$ Million) Analysis 2018 to 2023 and Forecast, 2024 to 2034
6.1. Historical Market Value (US$ Million) Analysis, 2018 to 2024
6.2. Current and Future Market Value (US$ Million) Projections, 2024 to 2034
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Test Type
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Million) By Test Type, 2018 to 2023
7.3. Current and Future Market Size (US$ Million) and Forecast ty Test Type, 2024 to 2034
7.3.1. Blood Tests:
7.3.1.1. C-Reactive Protein Testing Kits
7.3.1.2. Antibody Testing Kits
7.3.1.2.1. Antinuclear Antibodies (ANA) Test
7.3.1.2.2. Anti-CCP antibody testing
7.3.1.3. ESR Tests and CBC
7.3.2. Imaging Tests
7.3.2.1. X-rays Scans
7.3.2.2. HRCT Scans
7.3.3. Lung Biopsy
7.4. Market Attractiveness Analysis by Region
8. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Indication
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis by Indication, 2018 to 2023
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Indication, 2024 to 2034
8.3.1. Idiopathic pulmonary fibrosis (IPF)
8.3.2. Rheumatoid Arthritis Interstitial Lung Disease (RA-ILD)
8.3.3. Drug-induced pulmonary fibrosis
8.3.4. COVID-19-related pulmonary fibrosis
8.3.5. Pneumoconiosis
8.3.6. Sarcoidosis
8.3.7. Others
8.4. Market Attractiveness Analysis By Test
9. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) By End User, 2018 to 2023
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast by End User, 2024 to 2034
9.3.1. Hospitals
9.3.2. Specialty Clinics
9.3.3. Diagnostic Laboratories
9.3.4. Diagnostic Imaging Centers
9.4. Market Attractiveness Analysis by End User
10. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Region
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Trend Analysis by Region, 2018 to 2023
10.3. Current and Future Market Size (US$ Million) and Forecast by Region, 2024 to 2034
10.3.1. North America
10.3.2. Latin America
10.3.3. East Asia
10.3.4. South Asia and Pacific
10.3.5. Western Europe
10.3.6. Eastern Europe
10.3.7. Middle East and Africa
10.4. Market Attractiveness Analysis by Region
11. North America Market Analysis 2018 to 2023 and Forecast 2024 to 2034
11.1. Introduction
11.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
11.3.1. By Country
11.3.1.1. USA
11.3.1.2. Canada
11.3.1.3. Mexico
11.3.2. By Test Type
11.3.3. By Indication
11.3.4. By End User
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Test Type
11.4.3. By Indication
11.4.4. By End User
11.5. Market Trends
11.6. Drivers and Restraints - Impact Analysis
11.7. Country Level Analysis and Forecast
11.7.1. USA Market Analysis
11.7.1.1. Introduction
11.7.1.2. Market Analysis and Forecast by Market Taxonomy
11.7.1.2.1. By Test Type
11.7.1.2.2. By Indication
11.7.1.2.3. By End User
11.7.2. Canada Market Analysis
11.7.2.1. Introduction
11.7.2.2. Market Analysis and Forecast by Market Taxonomy
11.7.2.2.1. By Test Type
11.7.2.2.2. By Indication
11.7.2.2.3. By End User
11.7.3. Mexico Market Analysis
11.7.3.1. Introduction
11.7.3.2. Market Analysis and Forecast by Market Taxonomy
11.7.3.2.1. By Test Type
11.7.3.2.2. By Indication
11.7.3.2.3. By End User
12. Latin America Market Analysis 2018 to 2023 and Forecast 2024 to 2034
12.1. Introduction
12.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Chile
12.3.1.3. Rest of Latin America
12.3.2. By Test Type
12.3.3. By Indication
12.3.4. By End User
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Test Type
12.4.3. By Indication
12.4.4. By End User
12.5. Market Trends
12.6. Drivers and Restraints - Impact Analysis
12.7. Country Level Analysis and Forecast
12.7.1. Brazil Market Analysis
12.7.1.1. Introduction
12.7.1.2. Market Analysis and Forecast by Market Taxonomy
12.7.1.2.1. By Test Type
12.7.1.2.2. By Indication
12.7.1.2.3. By End User
12.7.2. Chile Market Analysis
12.7.2.1. Introduction
12.7.2.2. Market Analysis and Forecast by Market Taxonomy
12.7.2.2.1. By Test Type
12.7.2.2.2. By Indication
12.7.2.2.3. By End User
13. East Asia Market Analysis 2018 to 2023 and Forecast 2024 to 2034
13.1. Introduction
13.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
13.3.1. By Country
13.3.1.1. China
13.3.1.2. Japan
13.3.1.3. South Korea
13.3.2. By Test Type
13.3.3. By Indication
13.3.4. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Test Type
13.4.3. By Indication
13.4.4. By End User
13.5. Market Trends
13.6. Drivers and Restraints - Impact Analysis
13.7. Country Level Analysis and Forecast
13.7.1. China Market Analysis
13.7.1.1. Introduction
13.7.1.2. Market Analysis and Forecast by Market Taxonomy
13.7.1.2.1. By Test Type
13.7.1.2.2. By Indication
13.7.1.2.3. By End User
13.7.2. Japan Market Analysis
13.7.2.1. Introduction
13.7.2.2. Market Analysis and Forecast by Market Taxonomy
13.7.2.2.1. By Test Type
13.7.2.2.2. By Indication
13.7.2.2.3. By End User
13.7.3. South Korea Market Analysis
13.7.3.1. Introduction
13.7.3.2. Market Analysis and Forecast by Market Taxonomy
13.7.3.2.1. By Test Type
13.7.3.2.2. By Indication
13.7.3.2.3. By End User
14. South Asia and Pacific Market Analysis 2018 to 2023 and Forecast 2024 to 2034
14.1. Introduction
14.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
14.3.1. By Country
14.3.1.1. India
14.3.1.2. ASEAN Countries
14.3.1.3. Australia and New Zealand
14.3.1.4. Rest of South Asia and Pacific
14.3.2. By Test Type
14.3.3. By Indication
14.3.4. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Test Type
14.4.3. By Indication
14.4.4. By End User
14.5. Market Trends
14.6. Drivers and Restraints - Impact Analysis
14.7. Country Level Analysis and Forecast
14.7.1. India Market Analysis
14.7.1.1. Introduction
14.7.1.2. Market Analysis and Forecast by Market Taxonomy
14.7.1.2.1. By Test Type
14.7.1.2.2. By Indication
14.7.1.2.3. By End User
14.7.2. ASEAN Countries Market Analysis
14.7.2.1. Introduction
14.7.2.2. Market Analysis and Forecast by Market Taxonomy
14.7.2.2.1. By Test Type
14.7.2.2.2. By Indication
14.7.2.2.3. By End User
14.7.3. Australia and New Zealand Market Analysis
14.7.3.1. Introduction
14.7.3.2. Market Analysis and Forecast by Market Taxonomy
14.7.3.2.1. By Test Type
14.7.3.2.2. By Indication
14.7.3.2.3. By End User
15. Western Europe Market 2018 to 2023and Forecast 2024 to 2034
15.1. Introduction
15.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. UK
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Nordic Countries
15.3.1.8. Rest of Western Europe
15.3.2. By Test Type
15.3.3. By Indication
15.3.4. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Test Type
15.4.3. By Indication
15.4.4. By End User
15.5. Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Country Level Analysis and Forecast
15.7.1. Germany Market Analysis
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast by Market Taxonomy
15.7.1.2.1. By Test Type
15.7.1.2.2. By Indication
15.7.1.2.3. By End User
15.7.2. France Market Analysis
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast by Market Taxonomy
15.7.2.2.1. By Test Type
15.7.2.2.2. By Indication
15.7.2.2.3. By End User
15.7.3. Spain Market Analysis
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast by Market Taxonomy
15.7.3.2.1. By Test Type
15.7.3.2.2. By Indication
15.7.3.2.3. By End User
15.7.4. Italy Market Analysis
15.7.4.1. Introduction
15.7.4.2. Market Analysis and Forecast by Market Taxonomy
15.7.4.2.1. By Test Type
15.7.4.2.2. By Indication
15.7.4.2.3. By End User
15.7.5. BENELUX Market Analysis
15.7.5.1. Introduction
15.7.5.2. Market Analysis and Forecast by Market Taxonomy
15.7.5.2.1. By Test Type
15.7.5.2.2. By Indication
15.7.5.2.3. By End User
15.7.6. Nordic Countries Market Analysis
15.7.6.1. Introduction
15.7.6.2. Market Analysis and Forecast by Market Taxonomy
15.7.6.2.1. By Test Type
15.7.6.2.2. By Indication
15.7.6.2.3. By End User
15.7.7. United Kingdom Market Analysis
15.7.7.1. Introduction
15.7.7.2. Market Analysis and Forecast by Market Taxonomy
15.7.7.2.1. By Test Type
15.7.7.2.2. By Indication
15.7.7.2.3. By End User
16. Eastern Europe Market Analysis 2018 to 2023 and Forecast 2024 to 2034
16.1. Introduction
16.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
16.3.1. By Country
16.3.1.1. Russia
16.3.1.2. Hungary
16.3.1.3. Poland
16.3.1.4. Rest of Eastern Europe
16.3.2. By Test Type
16.3.3. By Indication
16.3.4. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Test Type
16.4.3. By Indication
16.4.4. By End User
16.5. Market Trends
16.6. Drivers and Restraints - Impact Analysis
16.7. Country Level Analysis and Forecast
16.7.1. Russia Market Analysis
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast by Market Taxonomy
16.7.1.2.1. By Test Type
16.7.1.2.2. By Indication
16.7.1.2.3. By End User
16.7.2. Hungary Market Analysis
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast by Market Taxonomy
16.7.2.2.1. By Test Type
16.7.2.2.2. By Indication
16.7.2.2.3. By End User
16.7.3. Poland Market Analysis
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast by Market Taxonomy
16.7.3.2.1. By Test Type
16.7.3.2.2. By Indication
16.7.3.2.3. By End User
17. Middle East and Africa Market Analysis 2018 to 2023 and Forecast 2024 to 2034
17.1. Introduction
17.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
17.3.1. By Country
17.3.1.1. Saudi Arabia
17.3.1.2. Türkiye
17.3.1.3. South Africa
17.3.1.4. Other African Union
17.3.1.5. Rest of MEA
17.3.2. By Test Type
17.3.3. By Indication
17.3.4. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Test Type
17.4.3. By Indication
17.4.4. By End User
17.5. Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Country Level Analysis and Forecast
17.7.1. Saudi Arabia Market Analysis
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast by Market Taxonomy
17.7.1.2.1. By Test Type
17.7.1.2.2. By Indication
17.7.1.2.3. By End User
17.7.2. Türkiye Market Analysis
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast by Market Taxonomy
17.7.2.2.1. By Test Type
17.7.2.2.2. By Indication
17.7.2.2.3. By End User
17.7.3. South Africa Market Analysis
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast by Market Taxonomy
17.7.3.2.1. By Test Type
17.7.3.2.2. By Indication
17.7.3.2.3. By End User
17.7.4. Other African Union Market Analysis
17.7.4.1. Introduction
17.7.4.2. Market Analysis and Forecast by Market Taxonomy
17.7.4.2.1. By Test Type
17.7.4.2.2. By Indication
17.7.4.2.3. By End User
18. Market Structure Analysis
18.1. Market Share Analysis of Top Sponsors
19. Competition Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Branding and Promotional Strategies by Key Stakeholders
19.4. Key Competitive Deep Dive
19.4.1. Roche Diagnostics
19.4.1.1. Overview
19.4.1.2. Services Portfolio
19.4.1.3. Key Financials
19.4.1.4. SWOT Analysis
19.4.1.5. Key Developments
19.4.1.6. Sales Footprint
19.4.1.7. Strategy Overview
19.4.2. Siemens Healthineers
19.4.3. Bio-Rad Laboratories
19.4.4. Eagle Biosciences, Inc.
19.4.5. Biogenix Inc. Pvt. Ltd.
19.4.6. Diagnostic Automation/Cortez Diagnostics Inc.
19.4.7. BioSupply Ltd.
19.4.8. Bio-Diagnostics Ltd.
19.4.9. MERIDIAN BIOSCIENCE
19.4.10. Weldon Biotech, Inc.
19.4.11. Getein Biotech, Inc.
19.4.12. Creative Diagnostics
19.4.13. Beijing Strong Biotechnologies, Inc.
19.4.14. Merck KGaA
19.4.15. CTK Biotech, Inc.
19.4.16. Personal Diagnostics
19.4.17. Thermo Fisher Scientific Inc.
20. Assumptions and Acronyms Used
21. Research Methodology
Healthcare
January 2023
REP-GB-16356
300 pages
Explore Healthcare Insights
View Reports
Pulmonary Fibrosis Biomarker Market
